tbuckley/cabot-search huggingface dataset:
AB0940 Efficacy and safety of platelet rich plasma peri-neural injection in treatment of diabetic neuropathy: double blind randomized controlled trial
Authors: M Hassanien, Y Saad, A Alawamy, WA Khalifa, D Abdelkarem
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Neuropathy is a common complication of diabetes mellitus (DM) not only leads to an impaired quality of life, but also to an increased morbidity and mortality.Autologous platelet-rich plasma is easy and cost-effective method. Platelet-derived angiogenesis factor capable of stimulating new capillary growth by inducing migration of endothelial cells, influence the process of angiogenesis and revascularisation. <h3>Objectives</h3> evaluate the clinical efficacy and safety of perineural PRP injection in the treatment of diabetic neuropathy (DN) compared to tradition medical treatment. <h3>Methods</h3> Sixty patients were selected from Endocrinology unit Department of Internal medicine, Assuit university Hospital, Egypt had type II diabetes mellitus neuropathy (DN) of at least 5 years duration of symptoms, regardless of age and gender double blindly divided into two groups, both groups had control blood glucose. Group I underwent PRP preineural injection under ultrasound guidance and group II underwent medical treatment. Baseline pain and nerve conduction study of upper and lower limb nerves and sural nerve conduction studies, F-wave. nerve conduction study were determined at 3 months after the procedure. Primary outcome was the total effective rate. The total effective rate = (the number of patients with significant effect+ the number of patients with effect)/total number of patients. A "significant effect" meant that limb pain, numbness, and fatigue were significantly reduced, nighttime sleep was improved, and NCV from electromyography increased &gt;5 m/s or returned to normal. An "effect" meant that the symptoms mentioned above were relieved, and NCV compared with pre-treatment increased &lt;5 m/s. "Failure" meant that the symptoms did not improve, and there were no changes in NCV electromyography <h3>Results</h3> We recruited 60 diabetic patients (type II) with peripheral neuropathy with a mean age 35.27±12.86 years with disease duration of 7.42±3.51 years. Of these, 56% cases with upper limb nerves neuropathy only while the rest 44% had sural nerve plus upper limb nerves neuropathy. Nerve conduction study showed axonal affection in only 26% and all had delayed distal latency and prolonged motor conduction velocities. generalized DN is found in 70% of total patients and 30% of had focal Entrapment of the nerve includes median neuropathy at the wrist 50%, ulnar neuropathy at the elbow 30% and peroneal neuropathy at the knee 20% and no patients had radiculoplexus neuropathies. <h3>Conclusions</h3> Autologous platelet-rich plasma is an easy and cost-effective method as a treatment of diabetic peripheral neuropathy. <h3>Disclosure of Interest</h3> None declared
THU0764-HPR What moves the rheumatologist? unravelling decision making in ssc referral – a qualitative study
Authors: JK Stöcker, E Cup, R Nijhuis-van der Sanden, B Staal, M Vonk, F van den Hoogen, E van den Ende
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Well-coordinated multidisciplinary non-pharmacological care is considered to be a cornerstone in the management of patients with systemic sclerosis (SSc). However, unmet information and healthcare needs are found to be common in patients with SSc [1]. In addition, referrals by rheumatologists9 do not always correspond with potential treatment goals as identified by health professionals (HP)[2]. <h3>Objectives</h3> The aim of this study was to gain insight in the perspective of rheumatologists about the referral process of SSc patients to non-pharmacological care and to identify starting points for its optimisation. <h3>Methods</h3> Semi structured in-depth interviews were held with 13 out of 24 rheumatologists, specialised in SSc management, from different Dutch university and regional medical centres. The qualitative data analysis used an inductive thematic analysis by moving through a process of coding in layers of abstraction and interpretation: familiarization with data, generating initial codes, grouping similar codes in categories, discussing categories, searching for themes among categories, reviewing themes, defining and naming themes, and producing the final report. <h3>Results</h3> One major theme was identified as influencing decision making: "beliefs" and its three sub themes: a) beliefs about one9s own professional role; b) beliefs about the patients9 ability to take an active role in managing the disease and c) beliefs about the added value of non-pharmacological care. We also found an additional theme reflecting the "needs" of the rheumatologists regarding professional multidisciplinary collaboration (Figure 1). Another remarkable finding to be further explored was the discrepancy we found between the reliance of rheumatologists on established routines with regard to when and to whom to refer and the low confidence in HPs competencies on the other hand. <h3>Conclusions</h3> The results of our study give insight that rheumatologists base their referral decisions on complex reasoning mindlines and beliefs about their own professional role, the patient9s role and HP competencies. <h3>References</h3> Willems, L. M., Kwakkenbos, L., Leite, C. C., Thombs, B. D., van den Hoogen, F. J., Maia, A. C., &amp; van den Ende, C. M. (2014). Frequency and impact of disease symptoms experienced by patients with systemic sclerosis from five European countries. Clinical And Experimental Rheumatology, 32(6 Suppl 86), S-88–93. Schouffoer, A., Zirkzee, E., Henquet, S., Caljouw, M., Steup-Beekman, G., Laar, J., &amp; Vlieland, T. (2011). Needs and preferences regarding health care delivery as perceived by patients with systemic sclerosis. Clinical Rheumatology, 30(6), 815–824. doi:10.1007/s10067–010–1645–6. <h3>Disclosure of Interest</h3> None declared
Correction: Zika virus has oncolytic activity against glioblastoma stem cells
Authors: Zhe Zhu, Matthew J. Gorman, Lisa D. McKenzie, Jiani N. Chai, Christopher G. Hubert, Briana C. Prager, Estefania Fernandez, Justin M. Richner, Rong Zhang, Chao Shan, Eric Tycksen, Xiuxing Wang, Pei-Yong Shi, Michael S. Diamond, Jeremy N. Rich, Milan G. Chheda
Journal: The Journal of Experimental Medicine (2017)
Cancer care coordination systematic review and meta-analysis: Twenty-two years of empirical studies.
Authors: Sherri Sheinfeld Gorin, David Haggstrom, Kathleen Fairfield, Paul Han, Paul Krebs, Steven B. Clauser
Journal: Journal of Clinical Oncology (2013)

6536 Background: To our knowledge, no systematic review of empirical papers describing cancer care coordination interventions has yet been conducted. The aim of this presentation is to describe the methods and findings from a systematic review and meta-analysis of all empirical papers describing cancer care coordination published between 1990-2012. Methods: Of 1241 abstracts collected from a search of PubMed and EMBASE, 108 studies were retrieved and reviewed; 49 were included in the systematic review. Each study had US or Canadian adult or child participants; each paper had comparison or control groups, measures, samples, and/or interventions. Two researchers independently applied a standardized search strategy, coding scheme, and on-line coding program to each study. Eight RCT’s met additional criteria for meta-analysis; a random effects estimation model was used for data analysis. Results: Among the 49 articles included in our systematic review, those that included implicit or explicit definitions of cancer care coordination described four components: (1) roles and models for communication and transfer of care between primary care physicians and oncologists during active treatment and survivorship; (2) care navigation through designated personnel or telecommunication processes among care team members; (3) treatment summaries and survivorship care plans; and (4) multidisciplinary communication accompanying patient and practice management within the framework of the Chronic Care Model (N=14). We found a medium-sized effect of cancer care coordination on care usage outcomes among the randomized clinical trials (e.g., reduced Emergency Department visits; g = 0.37 [95% CI = 0.29 - 0.44], I 2 = .000. Fail-safe N = 86). Conclusions: The findings from this current systematic review and meta-analysis will contribute to the evidence base on strategies that can improve the coordination of cancer care, particularly for patients with multiple chronic conditions, and thereby advance the goals of health care reform in the US.
AB1218-HPR Effectiveness of platelet-rich plasma on function and performance in patients with knee osteoarthritis: preliminary results
Authors: DC Sarac, B Unver, S Cekmece, M Erduran
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoarthritis is one of the most painful conditions and the most frequent cause of functional limitation and disability. There are variety of methods used in osteoarthritis (OA) treatment, including, physical therapy, exercise, intraarticular injections, surgery, etc. Platelet-rich Plasma (PRP) is a relatively new autologous biologic treatment that is used for stimulating cartilage healing process and improving the symptoms. Although the effects of PRP injection on pain and function investigated before, as to our knowledge there are no studies related to performance. <h3>Objectives</h3> Aim of this study was to investigate effectiveness of PRP on improving function and performance in patients with knee osteoarthritis. <h3>Methods</h3> This study included 28 patients (16 F, 12 M) who were affected by grade 1–3 bilateral knee OA according to Kellgren-Lawrence Scale. Patients received three injections of PRP that were performed at monthly intervals by the same doctor. All patients were evaluated before and six months after the first injection. Primary outcome measures were: Stair Climbing Test (SCT), 50-Foot Walk Test (50 FWT), 30-sec Chair Stand Test (30 CST) and Timed Up and Go Test (TUG), IOWA Score. Additionally, Hospital for Special Surgery Score (HSS) was also recorded as a secondary outcome measure. Wilcoxon signed-rank test is used for interpreting the differences between before and after the injections. <h3>Results</h3> All patients completed the study with no adverse effects. The mean age of the patients were 59±7.66 years. Improvements were determined for all outcome measures after 6 months regard to baseline results (p&lt;0.01) (Table 1). <h3>Conclusions</h3> Our preliminary findings show that PRP is safe and effective autologous biologic agent that might improve function and performance in patients with mild to moderate knee OA and; could be considered as a treatment option in patients with knee OA. <h3>Disclosure of Interest</h3> None declared
Thermo-sensitive hydrogel drug delivery system for improved pharmacokinetic profile of doxorubicin after intratumoral injection in tumor bearing mice
Authors: Ahmed Al-Abd, Soo-Hyun Kim, Soo-Chang Song, Hyo-Jeong Kuh
Journal: Cancer Research (2008)

5745  Local drug therapy is suggested to improve local control and to reduce systemic side effects for human solid tumors. Drug delivery system (DDS) is necessary to achieve controlled release of anti-cancer drugs within tumor tissue. Thermo-sensitive poly-organophosphazene hydrogel is a novel injectable polymer that transforms from sol to gel state at body temperature. Doxorubicin (DOX) is a cytotoxic drug that is frequently used for the treatment of several hematological and solid malignancies; however, it suffers from dose limiting systemic toxicities. In this study, we evaluated the local and systemic pharmacokinetics of DOX when given as intratumoral local injection (30 mg/kg) either in poly-organophosphazene hydrogel or solution in human gastric tumor xenograft-bearing mice. A sensitive, specific yet simple HPLC method was developed and used for quantification of DOX in plasma, tumor and other tissues. In tumor tissue, Cmax of DOX was 2.2 folds lower but T1/2 was 1.8 folds longer for hydrogel compared to that of solution, which resulted in similar AUCtumor for both formulations. Drug retention in tumor tissue was markedly enhanced: about 35% and 2% of the dose was retained within tumor compartment after one week, for hydrogel and solution, respectively. On the other hand, the plasma Cmax of DOX was 2.7 folds lower for hydrogel, and T1/2 was equivalent for both formulations. Consequently, AUCplasma was 2 folds lower for hydrogel compared to that of solution, indicating less systemic exposure. Tissue distribution of DOX was also significantly decreased when given in hydrogel compared to solution: the AUCtissue was 2 to 7 folds lower and tissue Cmax was 7-15 folds lower for hydrogel compared to solution, suggesting decreased chance of drug-induced toxicity in normal tissues. Tumor growth inhibition was not significantly different between both formulations. Overall, poly-organophosphazene DDS improved DOX pharmacokinetics with longer drug retention in tumor tissue and lower drug exposure in plasma and other tissues. These data suggest that thermo-sensitive poly-organophosphazene hydrogel may be a promising DDS for intratumoral administration of DOX, which warrants further evaluation.  Key words-Doxorubicin, poly-organophosphazenes, Pharmacokinetics, DDS.
THU0403 Urate-lowering treatment and risk of incident urolithiasis in people with gout: a nested case-control study
Authors: C-F Kuo, J-S Chen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> A higher risk of urolithiasis has been reported in gout patients. However, whether urate-lowering treatments, including both xanthine oxidase inhibotors and uricosuric agents, are beneficial to reduce the risk or urolithiasis in gout patients has not been examined. <h3>Objectives</h3> To investigate the independent associations between urate-lowering treatment (ULT) and the risk of urolithiasis in incident gout patients. <h3>Methods</h3> We conducted a nested case-control study based on the Taiwan National Health Insurance Research Database (NHIRD), which was used to identify 473,858 newly diagnosis gout patients during the period from January 1, 2000 through December 31, 2004. All these patients were followed until December 31, 2013. We considered patients who first diagnose incident urolithiasis after the date of entry cohort (gout onset) as cases and the diagnostic date was defined as index date. Each case was matched up to five eligible controls whose follow-up period included the case9s index date by sex, birth of year and gout diagnosis year. And the index date of case was assigned to the matched controls. Odds ratios (ORs) and 95% confidence interval (CI) of urolithiasis associated with cumulative defined daily dose (cDDD) of xanthine oxidase inhibitor and uricosuric agents were main ourcome measures. <h3>Results</h3> Gout patients with incident urolithiasis (n=32,654) occurring after the initial diagnosis of gout aged 20–79 were age- and sex-matched 1:5 to 163,270 gout patients without urolithiasis. After adjusting for age, sex, urbanization status, income, occupation, and pertinent drugs and comorbidities, the OR of urolithiasis associated with use of ULT among gout patients were 1.04 (95% CI 1.00 to 1.07) for those with 28–90 cDDD, 0.95 (95% confidence interval 0.91–0.99) for 91–365 cDDD and 0.77 (95% confidence interval 0.73–0.82) for &gt;365 cDDD, compared with those with a cDDD &lt;28. The OR (95% CI) for urolithiasis associated with xanthine oxidase inhibitor use was 0.94 (0.89–0.99) for 28–90 cDDD, 0.90 (0.84–0.97) for 91–365 cDDD and 0.73 (0.63–0.83) for &gt;365 cDDD. For uriscouric agents, the OR (95% CI) for urolithiasis among those with 28–91, 91–365 and &lt;365 cDDD were 1.04 (1.01, 1.08), 0.94 (0.90–0.98) and 0.78 (0.73–0.84), respectively. <h3>Conclusions</h3> Higher ULT consumption was associated with a lower risk of urolithiasis. Xanthine oxidase inhibitors associated with reduced urolithiasis risk consistently across the range of consumption studied but for uricosuric agents inadequate cumulative dose results in a higher risk despite the risk reduced gradually with a higher cumulative dose. <h3>Disclosure of Interest</h3> None declared
Multimodal Brain Analysis of Functional Neurological Disorders: A Functional Stroke Mimic Case Series
Authors: Enrico Premi, Alberto Benussi, Silvia Compostella, Nicola Gilberti, Veronica Vergani, Ilenia Delrio, Raffaella Spezi, Massimo Gamba, Angelo Costa, Roberto Gasparotti, Mauro Magoni, Alessandro Padovani, Barbara Borroni
Journal: Psychotherapy and Psychosomatics (2017)
AB0514 The relationship between serum level of c-terminal telopeptide of type i collagen with course of systemic lupus erythematosus and structural and functional state of bone tissue
Authors: S Shevchuk, L Denyschych, L Marynych
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> It is well known, that the incidence of osteoporosis in patients with systemic lupus erythematosus (SLE) is higher compared to the population level. Its severity in patients with SLE is associated with a number of factors: female gender, disease activity, damage index, glucocorticoid therapy etc. One of metabolic factors indicating the reducing bone mineral density (BMD) is the level of C-terminal telopeptide of type I collagen (CTX). Its place in the formation of osteoporosis in SLE patients is poorly understood, as well as its relationship with the course of the disease. <h3>Objectives</h3> The aim of study was to determine serum level of CTX in the SLE patients and its relationship with structural and functional state of bone tissue, course of the disease. <h3>Methods</h3> The study involved 58 SLE women (study group) and 29 healthy individuals (control group) representative by age and gender. The mean age of patients was 45,11±1,03 years. For every patient data were recorded on age, body mass index (BMI), chronic SLE damage (SLICC/ACR DI) and disease activity score (SLEDAI), cumulative glucocorticoid dose, serum concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP), bone resorption marker (CTX). Serum concentration of CTX was determined using ELISA test system "Nordic Bioscience Diagnostics A/S". Changes in BMD of the lumbar spine and proximal hip were determined by Dual-energy X-ray absorptiometry. <h3>Results</h3> It was established, that in patients with SLE serum level of C-terminal telopeptide of type I collagen was 1,15±0,03 ng/ml, while in the control group – 0,83±0,03 ng/ml, or was higher more than 19,0%. Violation of bone remodeling in patients with SLE was associated with reduced BMD, increased incidence of osteopenia and osteoporosis. Thus, the mean concentration of CTX in patients with osteoporosis was 1,63±0,04 ng/ml, while in patients with normal bone – 1,0±0,03 ng/ml. In SLE patients with osteopenia the level of C-terminal telopeptide of type I collagen was 1,23±0,04 ng/ml (higher more than 23% compared with the control group). Increased CTX practically had no correlation with age, duration of the disease, smoking and BMI. At the same time the serum CTX was associated with chronic SLE damage index (r =0,51), SLEDAI disease activity (r =0,41), concentration of IL-6 (r =0,45) and CRP (r =0,44) <h3>Conclusions</h3> Alterations of bone metabolism were found in 19% female SLE patients in the form of increasing serum CTX and closely associated with the severity and activity of the disease, high levels of CRP and IL-6 and did not depend on the age, disease duration, smoking and body mass index. <h3>Disclosure of Interest</h3> None declared
Mice deficient for ERAD machinery component Sel1L develop central diabetes insipidus
Authors: Daniel G Bichet, Yoann Lussier
Journal: Journal of Clinical Investigation (2017)

Deficiency of the antidiuretic hormone arginine vasopressin (AVP) underlies diabetes insipidus, which is characterized by the excretion of abnormally large volumes of dilute urine and persistent thirst. In this issue of the JCI, Shi et al. report that Sel1L-Hrd1 ER-associated degradation (ERAD) is responsible for the clearance of misfolded pro-arginine vasopressin (proAVP) in the ER. Additionally, mice with Sel1L deficiency, either globally or specifically within AVP-expressing neurons, developed central diabetes insipidus. The results of this study demonstrate a role for ERAD in neuroendocrine cells and serve as a clinical example of the effect of misfolded ER proteins retrotranslocated through the membrane into the cytosol, where they are polyubiquitinated, extracted from the ER membrane, and degraded by the proteasome. Moreover, proAVP misfolding in hereditary central diabetes insipidus likely shares common physiopathological mechanisms with proinsulin misfolding in hereditary diabetes mellitus of youth.
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Authors: Mark Yarchoan, Dongmei Xing, Lan Luan, Haiying Xu, Rajni B. Sharma, Aleksandra Popovic, Timothy M. Pawlik, Amy K. Kim, Qingfeng Zhu, Elizabeth M. Jaffee, Janis M. Taube, Robert A. Anders
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies. Experimental Design: To characterize the immune microenvironment in HCC, IHC staining was performed for CD8-positive T lymphocytes, PD-1–positive, and LAG-3–positive lymphocytes, CD163-positive macrophages, and PD-L1 expression in tumor and liver background from 29 cases of resected HCC. Results: Expression of CD8 was reduced in tumor, and expression of CD163 was reduced at the tumor interface. Positive clusters of PD-L1 expression were identified in 24 of 29 cases (83%), and positive expression of LAG-3 on tumor-infiltrating lymphocytes was identified in 19 of 29 cases (65%). The expression of both PD-L1 and LAG-3 was increased in tumor relative to liver background. No association between viral status or other clinicopathologic features and expression of any of the IHC markers investigated was noted. Conclusions: LAG-3 and PD-L1, two inhibitory molecules implicated in CD8 T-cell tolerance, are increased in most HCC tumors, providing a basis for investigating combinatorial checkpoint blockade with a LAG-3 and PD-L1 inhibitor in HCC. Clin Cancer Res; 23(23); 7333–9. ©2017 AACR.